Employing a proprietary next-generation antibody discovery and evolution platform, BioAtla LLC is described as a protein therapeutic company developing safer, more effective cancer drugs - novel monoclonal antibody and cell-based therapeutics. The firm's Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!) platforms - reported as protected by more than 150 issued patents and patent applications - enables the development of novel biologics (CABs) that have the characteristics of more selective targeting of cancer tissue and improved manufacturability. Improved selectivity for the tumor microenvironment - even when target is also found in normal tissue - not only improves safety but also expands the universe of potential drug targets, enabling the treatment of previously untreatable cancers. In January 2022, BioAtla announced a Clinical Collaboration with Bristol Myers Squibb to study Mecbotamab Vedotin (BA3011) and Ozuriftamab Vedotin (BA3021) in combination with Opdivo® (nivolumab) for treatment of solid tumors
